Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECORD 4: Rivaroxaban vs Enoxaparin for VTE Prevention in Total Knee Replacement
NCT00362232Phase 3Completed
- Sponsor
- Bayer
- Start
- Jun 2006
- Primary completion
- Jan 2007
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of rivaroxaban in venous thromboembolism (VTE) (2 arms), sponsored by Bayer. Primary endpoint: Composite Endpoint of Total Venous Thromboembolism at 16 days. Started Jun 2006; status: completed.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT00362232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00362232.